World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.
Advancing peptides for the treatment of rare endocrine and related diseases
We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
PROGRAMS
AZP-3601
Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.
AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3813
AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development as a potential treatment for acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.
LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.
Press Releases & Recent News
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
Download a PDF copy of this press release: EN FR LYON, France, and Cambridge, MA, May 16, 2022 — Amolyt …
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
Download a PDF copy of this press release: EN FR Top-line safety and efficacy data from ongoing clinical trial in …